Medline ® Abstract for Reference 64
of 'Neuroleptic malignant syndrome'
64
TI
Carbamazepine in the treatment of neuroleptic malignant syndrome.
AU
Thomas P, Maron M, Rascle C, Cottencin O, Vaiva G, Goudemand M
SO
Biol Psychiatry. 1998;43(4):303.
BACKGROUND:
Neuroleptic malignant syndrome (NMS) is a potentially lethal adverse effect to neuroleptic drugs.
METHODS:
We report on 2 cases where NMS dramatically improved with carbamazepine. Incidental removal and reapplication of carbamazepine attests to its effectiveness for this condition.
RESULTS:
A 34-year-old woman treated for a major depressive disorder experienced NMS with a phenothiazine. Her condition dramatically improved in 8 hours after she was administered carbamazepine. Since carbamazepine was discontinued, NMS recurred in 10 hours and remitted anew within less than 24 hours after reintroduction. A 31-year-old woman experiencing a schizoaffective disorder displayed NMS with aphenothiazine and a butyrophenone. NMS completely resolved within 8 hours after she was administered carbamazepine. NMS recurred within 12 hours after carbamazepine discontinuation.
CONCLUSIONS:
These data thus account for a cause-effect relationship between carbamazepine administration and NMS relief, and argue against the neuroleptic withdrawal to be responsible by itself for NMS relief.
AD
Department of Psychiatry, School of Medicine, Centre Hospitalier Regional et Universitaire, University of Lille, France.
PMID
